Lv11
18 积分 2021-09-04 加入
Molecular differences between poorly and well/moderately differentiated lung adenocarcinoma and their clinical implications
6小时前
已完结
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
1个月前
已完结
Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers
1个月前
已完结
Data from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
1个月前
已关闭
Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population
1个月前
已完结
肺癌常用标志物检测及临床应用专家共识（2026版）
3个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
5个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
6个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
6个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
6个月前
已完结
皖公网安备34019202002308
